Kalaris Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Kalaris Therapeutics, Inc. (KLRS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are KLRS insiders buying or selling?
In the last 12 months, Kalaris Therapeutics, Inc. insiders reported 2 open-market purchases ($6.2M) and 1 sale ($12.9K) — net buying of $6.2M. Since August 2020, Trabud has recorded 193 Form 4 filings for KLRS: 9 buys ($66.8M) and 184 sells ($46.3M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $5.0M by Srinivas Akkaraju (Director, 10% Owner) on Feb 18, 2026. SEC ↗
- The most recent open-market purchase was reported on May 22, 2026 (4 months ago).
Key Statistics (August 2020 – May 22, 2026)
Total Form 4 filings
193
SEC EDGAR
Insider filers
16
Insider buys (9)
$66.8M
Insider sells (184)
$46.3M
Insider sentiment
Net buyingNet insider flow of $20.4M in net buying since August 2020, and $6.2M in net buying over the last 12 months.
Recent KLRS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | Srinivas Akkaraju | Director, 10% Owner | Purchase | 244.3K | $4.83 | $1.2M | SEC ↗ |
| Mar 23, 2026 | Brett R Hagen | Chief Accounting Officer | Sale | 1.9K | $6.72 | $12.9K | SEC ↗ |
| Feb 18, 2026 | Srinivas Akkaraju | Director, 10% Owner | Purchase | 479.8K | $10.42 | $5.0M | SEC ↗ |
| Mar 27, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 907 | $8.97 | $8.1K | SEC ↗ |
| Feb 24, 2025 | Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Sale | 303 | $10.08 | $3.1K | SEC ↗ |
| Feb 24, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 96 | $10.08 | $967.28 | SEC ↗ |
| Feb 24, 2025 | Edward Miller | General Counsel | Sale | 106 | $10.08 | $1.1K | SEC ↗ |
| Jan 27, 2025 | Edward Miller | General Counsel | Sale | 52 | $9.50 | $494.03 | SEC ↗ |
| Jan 27, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 36 | $9.51 | $342.28 | SEC ↗ |
| Jan 27, 2025 | Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Sale | 129 | $9.50 | $1.2K | SEC ↗ |
| Jan 13, 2025 | Edward Miller | General Counsel | Sale | 409 | $0.44 | $180 | SEC ↗ |
| Jan 13, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 332 | $0.44 | $146.11 | SEC ↗ |
| Jan 13, 2025 | Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Sale | 979 | $0.44 | $430.86 | SEC ↗ |
| Nov 20, 2024 | Brett R Hagen | Chief Accounting Officer | Sale | 554 | $0.55 | $303.87 | SEC ↗ |
| Nov 20, 2024 | Vikas Sinha | Officer Title: President and Chief Financial Officer | Sale | 3.2K | $0.55 | $1.7K | SEC ↗ |
| Nov 20, 2024 | Edward Miller | General Counsel | Sale | 432 | $0.55 | $236.95 | SEC ↗ |
| Nov 20, 2024 | Diana Brainard | Chief Executive Officer | Sale | 8.7K | $0.55 | $4.8K | SEC ↗ |
| Nov 6, 2024 | Diana Brainard | Chief Executive Officer | Sale | 10.6K | $0.86 | $9.2K | SEC ↗ |
| Nov 6, 2024 | Edward Miller | General Counsel | Sale | 2.3K | $0.86 | $2.0K | SEC ↗ |
| Nov 6, 2024 | Brett R Hagen | Chief Accounting Officer | Sale | 1.7K | $0.86 | $1.4K | SEC ↗ |
| Nov 6, 2024 | Vikas Sinha | Officer Title: President and Chief Financial Officer | Sale | 5.1K | $0.86 | $4.4K | SEC ↗ |
| Oct 23, 2024 | Vikas Sinha | Officer Title: President and Chief Financial Officer | Sale | 3.4K | $0.77 | $2.6K | SEC ↗ |
| Oct 23, 2024 | Diana Brainard | Chief Executive Officer | Sale | 9.8K | $0.78 | $7.6K | SEC ↗ |
| Oct 23, 2024 | Brett R Hagen | Chief Accounting Officer | Sale | 965 | $0.77 | $746.29 | SEC ↗ |
| Oct 23, 2024 | Edward Miller | General Counsel | Sale | 1.4K | $0.77 | $1.1K | SEC ↗ |
Showing the 25 most recent of 193 Form 4 filings for Kalaris Therapeutics, Inc..
Most active KLRS insiders
- Brett R Hagen38 filings
- Vikas Sinha32 filings
- Diana Brainard28 filings
- Beek Jeroen B Van24 filings
- Edward Miller24 filings
Ask anything about KLRS insider activity
Use Trabud's AI agent to query Kalaris Therapeutics, Inc.'s Form 4 history in plain English — "Show me KLRS CEO purchases this year" or compare it against any other ticker.
Open the AI agentKLRS insider trading FAQ
Are Kalaris Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Kalaris Therapeutics, Inc. insiders reported 2 open-market purchases ($6.2M) and 1 sale ($12.9K) — net buying of $6.2M. Since August 2020, Trabud has recorded 193 Form 4 filings for KLRS: 9 buys ($66.8M) and 184 sells ($46.3M). Over the full record that is net buying of $20.4M.
How many insiders trade KLRS stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Kalaris Therapeutics, Inc.. The most recent filing was accepted on May 22, 2026.
Where does Trabud get KLRS insider trading data?
All KLRS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.